Neurogene Inc. Contractual Obligation
Neurogene Inc. (NGNE) had Contractual Obligation of $1.25 million as of 2024-06-30, per its 10-Q filed 2024-08-09.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligation · last filed 2024-08-09
- 2024-06-30: Contractual Obligation $1.25M.
- 2024-03-31: Contractual Obligation $1.29M.
- 2023-12-31: Contractual Obligation $1.29M.
- 2015-12-31: Contractual Obligation $2.19M.
| Period end | Contractual Obligation |
|---|---|
| 2024-06-30 | $1.25M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $1.29M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $1.29M 10-K · filed 2024-03-18 |
| 2015-12-31 | $2.19M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |